EUCTR2009-013763-19-IT进行中（未招募）不适用
Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 ?g) versus tiotropium (18 ?g) on Inspiratory Capacity in moderate COPD patients. - ND
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients eligible for inclusion in this study have to fulfil all of the following criteria: 1. Male and female adults aged ≥ 40 years who have signed an Informed Consent Form before any assessment is performed. 2. Co-operative outpatients with a clinical diagnosis of moderate COPD (moderate as classified by the GOLD Guidelines, 2007 (Appendix 1), confirmed by spirometry and including all of the following: a) Smoking history of at least 10 pack years (both current and ex-smokers); b) FEV1 < 80% and ≥ 50% of the predicted normal value (Visit 1); c) Post-bronchodilator FEV1/FVC < 0.7 (Visit 1) [Post refers to within 10-15 min of inhalation of 400 ?g (4x100 ?g) of salbutamol].
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to Visit 1. In the event of an exacerbation occurring during the run-in period (Visits 1-2), the patient must be discontinued from the study. The patient may be re-screened once the inclusion/exclusion criteria have been met. 2. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1. Patients who develop a respiratory tract infection between Visit 1 and Visit 2 must discontinue from the trial, but may be permitted to re-enroll at a later date once the inclusion/exclusion criteria have been met. 3. Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis or clinically significant bronchiectasis. 4. Patients with alpha-1-antitrypsin deficiency. 5. Patients with contraindications for tiotropium treatment including medical history of symptomatic prostatic hypertrophy, bladder neck obstruction, narrow angle glaucoma and moderate to severe renal impairment (creatinine clearance ≤ 50 mL/min). 6. Patients with a history of hypersensitivity to any of the study drugs or to drugs from similar drug classes. 7. Patients whose body mass index is less than 15 or greater than 40 kg/m2. 8. Any patient with lung cancer or a history of lung cancer. 9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotrophin (hCG) laboratory test (> 5 mIU/mL). 10. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of postmenopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone levels >40 mIU/mL or are using one or more of the following acceptable methods of contraception: a) surgical sterilization (e.g. bilateral tubal ligation, hysterectomy); b) hormonal contraception (implantable, patch, oral); c) double-barrier methods (any double combination of: intrauterine device, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). Acceptable methods of contraception may include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation. 11. Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
研究者
相似试验
进行中（未招募）
1 期
Multicenter, double blind, randomized, placebo controlled study of Testogel® (testosterone 50–100mg) to evaluate its efficacy and safety in men presenting with typical symptoms of partial androgen deficiency of aging males (PADAM) over a period of 6 months with 12 months open label follow-up - European Testogel study in PADAMEUCTR2004-001545-15-IESchering AG
已完成
不适用
Multicenter, randomized, double-blind, placebo controlled, parallel group trial to evaluate the effect of Vitamin D supplementation for fall preventioFallJPRN-UMIN000008361Tokushima university220
进行中（未招募）
1 期
Adjustment and improvement of metabolic control in night shift workers after administration of melatoniEUCTR2012-005254-30-DEniversity Medical Center Hamburg-Eppendorf144
进行中（未招募）
1 期
Placebo controlled study to assess the efficacy and safety of rapamycin in drug resistant epilepsy associated with tuberous sclerosis complexEUCTR2021-004548-64-PLThe Children's Memorial Health Institute200
进行中（未招募）
不适用
Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable dose of metformin BM18106type 2 diabetesMedDRA version: 6.1Level: PTClassification code 10049746EUCTR2004-004529-84-ITROCHE200